2021 is coming to an end, but the pace of the venture capital circle has not slowed down at the end of the year. What is noteworthy today is that the Hong Kong Stock Exchange announced the IPO pricing of Shangtang technology, and the first share of "Ai four dragons" will land in the capital market; The wind of carbon neutralization blew from the beginning of 2021 to the end of 2021. The track technology enterprise "carbon energy technology" announced that it had obtained tens of millions of yuan of round a financing led by Sequoia China seed fund; In addition, the preferred SaaS track reproduces large financing.
carbon neutral track heat does not decrease
Today, carbon neutralization technology company "carbon energy technology" announced the completion of tens of millions of yuan of round a financing. This round of financing is led by Sequoia China seed fund, followed by Qiji Chuangtan, and Yunxiu capital serves as the exclusive financial adviser.
Public information shows that "carbon energy technology" is a carbon utilization technology R & D and commercialization service provider, committed to the R & D and commercialization of carbon utilization technology and key hydrogen energy technologies. The landing of this round of financing also makes the track more lively.
Under the guidance of the "3060" goal, carbon neutralization has long been an investment highland for local giants. This year ushered in the first year of carbon neutral investment in the primary market. The layout of venture capital was unprecedentedly active. In the first half of this year alone, the investment scale reached a new high over the years, showing the characteristics of large single financing amount and active gathering of giants.
In this regard, some investors said that "carbon neutralization" is a long slope track with a time span of 40 years, and private equity investment will be one of its long-term power sources. However, this track with huge investment volume brings not only a challenge to PE / VC's financial strength and investment vision, but also a contest of time and patience.
the first share of the "Ai four dragons" landed on the HKEx
According to the announcement of the Hong Kong stock exchange, the final offering price of Shangtang technology's IPO in Hong Kong is set at HK $3.85 per share, and the issuance scale is HK $5.775 billion (about US $740 million); Trading on the stock exchange is expected to begin on December 30. After several setbacks, Shangtang technology will finally be listed on the HKEx at the end of 2021. This also means that Shangtang technology will become the first player to land in the capital market among the "Ai four dragons".
According to public data, Shangtang technology, established in October 2014, is an AI software company focusing on computer vision and in-depth learning technology. Its business covers four sectors: smart business, smart city, smart life and smart car. Together with Kuangshi technology, Yuncong technology and Yitu technology, it is known as the "Four Dragons of Chinese artificial intelligence computer vision", which also represents China's world-class leading level in this technology field.
According to the global Unicorn index 2021 released by Hurun Research Institute, Shangtang technology ranks 10th among China's "unicorns" with a valuation of 77 billion yuan.
SaaS + medical reproduction large amount financing
Today, the consumer healthcare SaaS platform "Lingjian" announced the completion of the D + round of financing, and the investors are Tongchuang Weiye and Gan Jiawei.
According to public data, "Lingjian" was established in 2015, focusing on the consumer medical, oral and medical beauty industries, aiming at promoting industrial reform with digital technology, and connecting upstream and downstream industries and ecological partners through SaaS + X model.
It is worth noting that this round is the second financing obtained by the company during the year. In June this year, it announced the completion of round D financing of US $100 million, which was led by Investcorp and overweight by investment institutions such as Jingwei venture capital, an old shareholder. In 2021, its frequent financing is only the epitome of the bustle of Enterprise Service SaaS track; Since this year, this field has maintained a rapid financing rhythm and gold absorption capacity, and most of them are front-line funds such as Sequoia China, Hillhouse capital, GGV capital and Jinshajiang venture capital.
As a subdivision track of enterprise services, "medical + SaaS" is further favored by capital due to the scarcity of resources and large digital space of the industry. Previously, some investors said that in the future, with the development of medical big data, artificial intelligence, Internet of things and other technologies, the medical industry, agriculture and other fields will take the lead in being transformed by AI and Internet of things supported systems or software services, and companies focusing on vertical industries such as medical, intelligent agriculture and finance will probably take the lead in "running out".
(Daily Economic News)
